Loading…
QINLOCK is a brand name for Ripretinib, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
5 Missed Dose 2024-08 Table of Contents Certain sections or subsections that are not applicable at the time of preparation of the most recent authorized product monograph are not listed. Recent Major Label Changes .....................................................................................................
2 Part 1: Health Professional Information ................................................................................... 4 1 Indications .......................................................................................................................
1 Pediatrics ............................................................................................................... 2 Geriatrics ...............................................................................................................
4 2 Contraindications ............................................................................................................ 4 3 Serious Warnings and Precautions Box .......................................................................
4 4 Dosage and Administration ........................................................................................... 1 Dosing Considerations ..........................................................................................
2 Recommended Dose and Dosage Adjustment ..................................................... 4 Administration ........................................................................................................ 5 Missed Dose ..........................................................................................................
8 5 Overdose .......................................................................................................................... 8 6 Dosage Forms, Strengths, Composition and Packaging ............................................
8 7 Warnings and Precautions ............................................................................................. 8 Carcinogenesis and Genotoxicity ......................................................................................
9 Cardiovascular .................................................................................................................. 9 Immune .............................................................................................................................
9 Monitoring and Laboratory Tests ...................................................................................... 9 Perioperative Considerations ..........................................................................................
10 Reproductive Health ........................................................................................................ 10 Skin .................................................................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
1 Special Populations ............................................................................................. 1 Pregnancy ....................................................................................................... 2 Breastfeeding ..................................................................................................
3 Pediatrics ......................................................................................................... 4 Geriatrics .........................................................................................................
12 8 Adverse Reactions ........................................................................................................ 1 Adverse Reaction Overview ................................................................................
2 Clinical Trial Adverse Reactions .......................................................................... 3 Less Common Clinical Trial Adverse Reactions.................................................. 4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry, and Other Quantitative Data ............................................................................................................
15 9 Drug Interactions .......................................................................................................... 2 Drug Interactions Overview .................................................................................
4 Drug-Drug Interactions ........................................................................................ 5 Drug-Food Interactions ........................................................................................ 6 Drug-Herb Interactions ........................................................................................
7 Drug-Laboratory Test Interactions ....................................................................... 18 10 Clinical Pharmacology ..................................................................................................
1 Mechanism of Action ........................................................................................... 2 Pharmacodynamics ............................................................................................. 3 Pharmacokinetics ................................................................................................
19 11 Storage, Stability, and Disposal .................................................................................. 21 Part 2: Scientific Information ...................................................................................................
22 13 Pharmaceutical Information ......................................................................................... 22 14 Clinical Trials […]